New York, May 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – RYAH Group, Inc’s (CSE:RYAH) (“RYAH” or the “Company”) wholly owned subsidiary, RYAH Medtech Inc. (“RYAH Medtech”), is pleased to announce that it has welcomed four new members to its business development team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer and Andrea Ferrari.
The newly added experts bring extensive experience and expertise in the medical and pharmaceutical industry: Steven Schultz joins RYAH with $350 million in sales and 35 years of experience, including acting as national account director at Johnson & Johnson; Warren Thompson, former national sales director at Ackermann U.S.A., brings 20 years of sales experience in the medical device industry; and Mitch Zimmer, who brings over 40 years of medical industry experience as an outstanding senior sales expert, manager, trainer and mentor.
The team will be focusing on expanding RYAH’s presence in multiple verticals within the North America plant-based and nutraceutical markets, including participation in clinical trials for the Company’s connected devices and custom software solutions in data analytics for doctors, clinics, hospitals and dispensaries.
Andrea Ferrari, former managing director of Aurora Italia, joins the RYAH team to enhance the brand's presence in the European market, bringing his unparalleled expertise into clinical research implementation.
“We are thrilled to announce these new appointments. This team has deep acumen in the medical device and related industries, which will allow us to capitalize on the changing regulatory environment and to bring this experience to an even wider group of clinical, medical and pharmaceutical clients worldwide,” says Gregory Wagner, CEO of RYAH and RYAH Medtech.
“We are excited to welcome the new Business Development team, who all have a proven record of facilitating long term business relationships with both corporate customers and medical industry luminaries,” says Sofiya Kleshchuk, Head of Client Relations at RYAH Medtech.
About RYAH Group, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both Internet of Things and Artificial Intelligence to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may,” “would,” “could,” “should,” “potential,” “will,” “seek,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions as they relate to the Company, including, the success of the Company’s clinical trials, the expansion of RYAH’s presence, and the results users may receive from using RYAH, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law
RYAH Medtech Inc Contacts:
Sofiya Kleshchuk
Client Relations
+1 917 210 0543
Invest@ryahgroup.com
Gregory Wagner, CEO
917 210 0543
Info@ryah.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com